Clinical Case Reports (Apr 2020)
Serum free light chains and multiple myeloma: Is it time to extend their application?
Abstract
Abstract In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents.
Keywords